盐酸坦索罗辛联合非那雄胺对延缓及预防BPH临床进展疗效观察.docVIP

盐酸坦索罗辛联合非那雄胺对延缓及预防BPH临床进展疗效观察[摘要] 目的：探讨坦索罗辛联合非那雄胺对延缓和预防良性前列腺增生临床进展性的疗效。方法：对具有前列腺增生临床进展高危因素的患者给予坦索罗辛联合非那雄胺治疗，观察治疗前后各项相关指标的变化，并进行统计学处理。结果：全部患者症状显著改善，临床进展的风险显著降低。结论：坦索罗辛联合非那雄胺能显著降低良性前列腺增生临床进展，显著减少急性尿潴留的发生和外科干预的风险。 [关键词] 良性前列腺增生；临床进展性；坦索罗辛；非那雄胺 [中图分类号] R697+.32 [文献标识码]B[文章编号]1674-4721（2011）07（c）-096-02 Efficacy observation of tamsulosin combined finasteride on delay and prevention the progression of BPH TAO Zhongjie Department of Surgery, Taihe Central Hospital of Dongpo District, Meishan City, Sichuan Province, Meishan 620039, China [Abstract] Objective: To investigate the efficacy of tamsulosin and finasteride on delay and prevention the clinical progression of benign prostatic hyperplasia efficacy (BPH). Methods: Patients with clinical progress risk factors of benign prostatic hyperplasia were treated with tamsulosin and finasteride. Observed the changes of the relevant indicators before and after treatment, and were given statistical analysis. Results: All symptoms of patients significantly improved and significantly reduced the risk of clinical progression. Conclusion: Tamsulosin and finasteride can significantly reduce the incidence of the clinical progression of benign prostatic hyperplasia. [Key words] Benign prostatic hyperplasia; Clinical progression; Tamsulosin; Finasteride 良性前列腺增生（benign prostatic hyperplasia，BPH）是老年男性的一种常见病，主要由于前列腺增生导致膀胱出口梗阻，表现为尿频、尿急、夜尿增多以及排尿困难等下尿路症状（lower urinary tract symptoms，LUTS），严重影响患者的生活质量，部分患者因症状恶化表现为临床进展性。本文探讨α1-受体阻滞剂联合5α-还原酶抑制剂对缓解LUTS、延缓和预防BPH临床进展、降低急性尿潴留（acute urinary retention，AUR）的发生和外科干预的风险的疗效。笔者收集了2005年6月～2009年5月的BPH患者资料，从中筛选出具有临床进展高危因素的患者共53例，给予坦索罗辛联合非那雄胺治疗。现报道如下： 1 资料与方法 1.1 入选标准 对BPH患者常规尿常规检查、直肠指检（digital rectal examination，DRE）、尿流率测定、B超测前列腺体积（prostate volume，PV）、残余尿量（postvoid residual urine volume，PVR）、血清前列腺特异性抗原（prostate specific antigen，PSA）测定以及国际前列腺症状评分（international prostate symptom score，IPSS）。满足下列条件者入选治疗：①IPSS评分≥8分；②PV＞30 ml；③最大尿液率（Maximum, urinary flow rate Qmax）≤12 ml/s；④PVR＞30 ml；